Thermo Fisher Scientific Inc. $TMO Stock: Pathway Financial Advisers LLC Cuts Holdings

Posted by Francis Steltz on Nov 6th, 2026

Pathway Financial Advisers LLC cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 74.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 400 shares of the medical research company’s stock after selling 1,187 shares during the quarter. Pathway Financial Advisers LLC’s holdings in Thermo Fisher Scientific were worth $270,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Kestra Private Wealth Services LLC raised its stake in shares of Thermo Fisher Scientific by 2.5% during the 3rd quarter. Kestra Private Wealth Services LLC now owns 15,628 shares of the medical research company’s stock valued at $10,550,000 after buying an additional 374 shares during the last quarter. Bfsg LLC acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $86,000. Chicago Partners Investment Group LLC boosted its stake in shares of Thermo Fisher Scientific by 16.4% in the third quarter. Chicago Partners Investment Group LLC now owns 2,266 shares of the medical research company’s stock worth $1,527,000 after buying an additional 319 shares during the last quarter. Ascent Group LLC boosted its stake in shares of Thermo Fisher Scientific by 9.5% in the third quarter. Ascent Group LLC now owns 12,380 shares of the medical research company’s stock worth $8,357,000 after buying an additional 1,075 shares during the last quarter. Finally, 3Chopt Investment Partners LLC grew its holdings in Thermo Fisher Scientific by 17.5% during the third quarter. 3Chopt Investment Partners LLC now owns 1,189 shares of the medical research company’s stock worth $803,000 after acquiring an additional 177 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 4.1%

TMO stock opened at $677.28 on Friday. The company’s 50-day simple moving average is $659.74 and its 200-day simple moving average is $554.40. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.71. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $712.17. The firm has a market cap of $250.95 billion, a P/E ratio of 35.72, a PEG ratio of 2.88 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, beating the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The firm had revenue of $12.14 billion during the quarter, compared to analyst estimates of $11.95 billion. During the same quarter in the previous year, the business earned $5.79 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 9.1% compared to the same quarter last year. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Barclays upped their price objective on Thermo Fisher Scientific from $750.00 to $775.00 and gave the stock an “overweight” rating in a research report on Thursday, October 22nd. Sanford C. Bernstein raised their price objective on shares of Thermo Fisher Scientific from $520.00 to $575.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Leerink Partners lifted their target price on shares of Thermo Fisher Scientific from $600.00 to $620.00 and gave the company an “outperform” rating in a report on Wednesday, July 22nd. Finally, Stifel Nicolaus lifted their target price on shares of Thermo Fisher Scientific from $650.00 to $775.00 and gave the company a “buy” rating in a report on Thursday, October 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $683.64.

View Our Latest Stock Analysis on TMO

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $77,982,284.75. This trade represents a 7.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the sale, the vice president owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 50,046 shares of company stock worth $30,779,192. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

Positive Sentiment: The board authorized up to $5 billion in share repurchases, replacing an authorization with $1 billion remaining. The new program has no expiration date and could support shareholder returns and demand for the stock. Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
Positive Sentiment: Thermo Fisher introduced lower-priced qPCR master mixes, positioning its products for labs seeking reliable testing tools while managing budgets. The launch may broaden product appeal, though its near-term financial impact is not specified. Thermo Fisher Scientific Introduces Value-Priced AmpSure Universal qPCR Master Mixes
Positive Sentiment: An investor-letter report cited improving biopharma spending and said TMO was a strong contributor after a 27% quarterly gain. That supports the demand outlook, but also highlights the stock’s recent run-up. Improving Biopharma Spending Lifts Thermo Fisher
Neutral Sentiment: Industry reports forecast growth in mRNA manufacturing, protein labeling and Q-TOF mass spectrometry markets, areas relevant to Thermo Fisher. These are broad market projections, not company-specific sales or earnings updates. mRNA Manufacturing Service Market Report 2026
Negative Sentiment: After substantial recent gains, investors may be taking profits; TMO’s elevated valuation could also make shares sensitive to market expectations. The articles provide no specific deterioration in the company’s outlook to explain the weakness.

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.